专访|德国病毒学家陆蒙吉:现阶段,大规模抗体检测很重要

2020-04-05 刘惠 澎湃新闻

“要界定无症状感染者,跟病人的主观感觉有关系。我认为讨论这个概念的时候要谨慎小心。” 杜伊斯堡-埃森大学医学院病毒研究所教授陆蒙吉近日在接受澎湃新闻专访时说道。

“要界定无症状感染者,跟病人的主观感觉有关系。我认为讨论这个概念的时候要谨慎小心。” 杜伊斯堡-埃森大学医学院病毒研究所教授陆蒙吉近日在接受澎湃新闻专访时说道。

新冠肺炎疫情这场自1918年西班牙大流感以来人类社会面临的最严重的健康危机依然在肆其毒焰。据美国约翰·霍普金斯大学发布的数据,截至北京时间4月5日凌晨,全球新冠肺炎确诊病例累计已超过117万例,逾6万人死亡。科学界相关领域的专家也在不停地加深对新冠病毒的了解,以期尽快找出克制它的方法。

继“群体免疫”思路之后,近日无症状感染者又成为这场疫情的焦点话题。《欧洲呼吸杂志》最新发表的、由钟南山院士与广州呼吸健康研究院关伟杰副研究员、深圳市人民医院陈荣昌教授撰写的社论文章强调,无症状患者可能是人传人重要传染源,必须重视新冠的早期诊断以及隔离确诊病例。

而人类对新冠病毒的进一步认识也将影响世界各国对这场疫情后续走势的预估和应对措施。德国著名病毒学家德罗斯滕3月25日称,感染新冠病毒后的病人会形成抗体,其中一部分无症状感染者可能在自己毫不察觉的情况下获得免疫,未来可以通过大规模抗体检测,核实这部分数据,这对整个疫情发展的建模和对未来的预测有非常重要的意义。

然而,目前对无症状感染者这一群体的认识还很有限,如何科学认定无症状感染者,无症状感染者的病毒传播力有多强,这一群体在全球范围内占多大比例等问题还有待回答。

陆蒙吉在接受澎湃新闻专访时也指出,我们目前对新冠病毒的认知非常有限,现在很多看法还只是猜测,之后可能会被推翻。而我们也需要在学习研究病毒的过程不断调整对策。如果无症状感染者的群体十分庞大,那新冠病毒或许就不那么可怕,各国的应对政策也都会相应调整。因此,通过大规模抗体检测筛查无症状感染者在现阶段很重要,既可以确定这一群体的规模,也可以判定其传播特征。一旦新冠病毒真的卷土重来,或者我们决定让社会恢复运作时,就可以凭此有目的性地去采取一些防护措施。

如何摸清很“主观”的无症状感染者有多少?

澎湃新闻:新冠肺炎无症状感染者近期引起了广泛关注,各国研究人员都在测这类人在感染者总人数中占比多少。我们该如何理解无症状感染者?他们的传染性如何?

陆蒙吉:无症状感染者是一个比较主观的定义。有些人身体状况很好,觉得自己没病;有些人症状很轻,就稍微咳嗽几下,在呼吸道感染疾病多发的冬天也比较正常,这种轻微症状容易被人忽略掉。所以要界定无症状感染者,跟病人的主观感觉有关系。

我认为讨论这个概念的时候要谨慎小心,说得太多大家会把许多不明情况的都归成了无症状感染者,但事实上这不是一个在医学上容易定义的东西。不排除有人不大愿意接受自己感染的事实,故意说没有症状。

对于无症状或者症状不明显的感染者,我们可以通过“血清学检测”摸索情况。不做血清检测永远搞不清楚所谓的无症状感染者到底有多少,他们传播病毒的特征是什么,我们又该如何防范。这是目前的当务之急。

澎湃新闻:血清检测是指抗体检测?它与核酸检测相比有何不同?

陆蒙吉:相比之下,血清(抗体)检测技术操作比较简单。它是对人体血液中的抗体水平进行检测。在疾病感染早期,人体内可能还没有产生抗体,所以它存在检测的窗口期,要用核酸检测。抗体检测最大的优势在于可以对病例进行排查筛查,大一点的实验室或生物技术公司每天做上万例的抗体检测不成问题。

德国在这次疫情暴发过程中有一个典型的聚集性感染的案例。北威州大量感染病例与2月15日在该州海因斯贝格县冈格尔特镇举行的一场狂欢节活动有关。

现在德国科研人员就在冈格尔特镇上做抗体检测普查。因为有很多人没有症状,只有筛查才能知道到底有多少人感染新冠病毒。镇上大概有12000多人,部分人群是核酸检测为阳性的,那么其他人到底是什么状态?等血清学检测结果出来以后,无症状感染者数量和占比就可以明确了。以这个镇子为案例,可以模拟出新冠病毒是如何从小范围到广泛传播的。通过让感染者回忆去过哪些场合、接触过哪些人,可以进一步了解新冠病毒的传播模式。

我们研究新冠病毒是从它大规模传播开始,才3个月的时间,对病毒的认知非常有限。现在很多看法还只是猜测,很多东西以后可能会被推翻。中国此前会以非典病毒(SARS)作为参照物来试图理解它,欧美则是用那边较常见的流感对比,但现在我们都发现了,新冠病毒既不是SARS,也不是流感。

澎湃新闻:您认为什么情况下有必要做这种大规模的抗体检测?每个人都需要做吗?

陆蒙吉:我认为大规模抗体检测对于现阶段很重要。无症状感染者显然不知道自己被感染,他做核酸检测也可能有假阴性的问题。但抗体检测不一样,在感染新冠病毒10天到15天后,最晚20天后,人就会出现抗体。所以可以用抗体检测追踪到无症状感染者。对于无症状感染者的传染性问题,可以通过追踪他们的密切接触者,找到答案。

要在学习研究病毒的过程中不断调整对策

澎湃新闻:如果检测发现这个无症状感染者群体非常大的话,是不是说明英国专家之前提出的群体免疫思路不可行?

陆蒙吉:不能这样简单地理解。假如说检测出来这个群体不大,那么我们目前的抗疫策略没什么问题。如果它非常大,我们整个监控、追踪、隔离的策略都要调整。

如果这个群体十分巨大,这个病是不是就没有那么可怕了?现在德国的病死率是1%,假如有10倍的人感染且无症状的话,死亡率马上就变成了0.1%。那大家对它整个态度会完全改变,可能欧洲就全部开放了,各国的应对政策都会相应调整。

意大利是一个比较不幸的情况,死亡率是德国的10倍,这里面有人口年龄结构、居住条件以及集体接触的文化习惯等原因。如果说在德国发现存在大量无症状感染者,政府可能不会继续要求餐厅娱乐场所停业了,民众也无需过度担心,大家可以采取一些注重保护弱势群体的策略。

澎湃新闻:德国疫情目前处于一个什么阶段?类似意大利或西班牙这样的大暴发情况有可能在德国出现吗?

陆蒙吉:目前疫情在德国大暴发的可能性比较小,但也无法保证。我们现在看到德国采取了很多举措,包括从3月22日德国就封闭了边境,娱乐餐饮、大型活动全部停掉,禁止两人以上的集会等。这些措施启动以后,德国最近新增病例的数字逐渐在下降。说明防疫措施的效果在逐渐体现出来,但它真正的效果如何要到本周末(4月5日)才能见分晓,也就是德国采取行动后14天以后。

14天之后的数据可以帮助我们判断,目前的措施够不够,数学模型也可以开始预测德国何时能走过疫情峰值。现在德国的目标就是坚持目前的措施,接下来是复活节假期,就像中国春节一样,这个假期很多人就呆在家里面,小孩子本来也不用上学,这段时间保持目前的措施没有难度。等4月20日假期结束后,我们可以再来关注德国会做什么决定,这个决定值得解读。

澎湃新闻:德国需要决定什么?

陆蒙吉:简单来说就是要挽救生命和金钱。一要控制疫情,二要保证经济不长期受损。目前德国政府很担心疫情对经济的冲击。所以4月20日视情况,德国一定会尽量恢复社会活动。

这么做意味着病毒传播频率回升,这是必然的,回升到一定阶段的时候,又必然会要求你拿出相应的对策。但到那时我们可能对病毒的认知增加了,可以有更优的对策。欧美这一波“拉平曲线”的操作除了防止卫生系统超负荷运转,也有赢得应对时间的作用。感染还是在继续,我们要做的是把让它处于一个可控的水平,这里面的技术含量非常高,要在学习研究病毒的过程中不断调整对策。

温度高的地方,目前很难说新冠病毒不流传

澎湃新闻:美国国家过敏症和传染病研究所所长福奇之前曾说,有迹象表明新冠病毒会呈季节性周期爆发,中国是否需要为疫情第二次暴发做准备?

陆蒙吉:现在说新冠病毒有季节性为时过早。过去我们已知的冠状病毒是有季节性的,到冬天它就传播得多一点,夏天就不怎么传播。但现在我们看到,新冠病毒跟我们过去已知的冠状病毒非常不同,传播模式是不能用过去我们已知的模式进行比较的。

新冠肺炎已经是一个大流行,感染的人口基数非常大,它在非洲、印度这些天气炎热国家的情况我们根本不好说。这些地方的人口流动说不定已经把病毒传到乡下了,但如果检测没跟上的话,实际传播情况是个黑洞。也就是说,在气温比较高的地区,目前很难说新冠病毒并不流传。

我建议中国如果有这个力量,应该去做这个工作。可以派一小支队伍到天气比较热的地方去,包括在非洲、印度那边去做个1万、2万、3万甚至10万份的检测,看看流传情况到底怎样?有了这个检测数据之后,我们才能预测到了夏天病毒的传播力会不会下降,传播范围和广度会不会减小。

澎湃新闻:现在包括中国在内的各国抗疫政策都是以检测和隔离为主,这种方式在之后是否也需要进一步调整?

陆蒙吉:中国人口基数大,城市人口密度大,所以目前的严防死守肯定要坚持一段时间。假如到天气热了病毒传播能力确实下降,这是运气,不能把希望寄托在这上面。如果新冠病毒真是季节性的,最晚到了冬天它还会再回来。

如我前面所说,现在当务之急是研究病毒的传播模式。这也是为什么要去筛查到底有多少无症状感染者,通过确定这个人群到底有多大,再判定它的传播特征。那么假如疫情卷土重来,或者我们决定让社会恢复运作的时候,就可以有目的性地去采取一些防护措施,包括该怎么做消毒,人与人的接触要避免什么动作。通过这些细致的调整,有希望把病毒传播力度控制在较低的水平,同时社会可以重新运转。

新冠病毒很狡猾,无论你怎么防堵,可能总有一些没检测出来的漏网之鱼。在人口密度高的地方,大家把口罩继续戴上,保证潜伏期的病人不传染他人,这也是很有用的。我想强调的是,持续研究病毒也很必要。要培养大众理性态度,不要过度害怕病毒,要探索找到可以恢复正常生活和控制病毒传播速度的平衡点。这不容易。

何时能恢复正常生活?

澎湃新闻:您对人们生活何时可以恢复正常有无预测?我们应该寄希望于疫苗吗?

陆蒙吉:考虑到安全性和有效性,研发疫苗至少要花1-1.5年的时间,这不是近期可以解决的问题。目前大家还在考虑2周或4周以后的事情,要预测1年以后的事情都说不好。

比如艾滋病疫苗研究了几十年,但是不成功。我们现在有最好的技术和方法,但不一定会做出有效的疫苗。另一个说起来有点怪的困境是,没有流传人群,就没有疫苗。我们要检测疫苗有效性的时候,可能已经找不到一个合适的群体来做实验了。打完疫苗会出现抗体、细胞免疫,这些指标被认为会对人类起保护作用,但它实际上能不能保护我们?这必须在一个病毒有流传的地区检测,在哪里检测会是一个问题。

还有安全性问题,如果疫苗打了副作用太大,那么没有人会去打。接种疫苗的副作用要控制在什么水平合适?60%的人口接种疫苗后,才能产生群体免疫的效果,这对疫苗的要求很高,要把不良事件控制在多少,才算是扯平了新冠病毒造成的人员死亡,我们可以算一算这个数学题。但是花了那么多的钱和精力研发疫苗,效果仅仅扯平是不够的。

至于我们的生活何时恢复正常,我没有办法预测。即便人类克服了新冠病毒之后,我们的生活也不会回到原来的状态。这次受到冲击最大的是经济。经济陷入长期停滞的话,各国的卫生体系、普通人的生活和健康又来拿什么保证呢?所以大家都在思考这个平衡点在什么地方。

基于我们目前对病毒的知识,要恢复一定的人流、物流往来也不是完全不可以,但要做好检测。可以靠提高口岸的检测能力,依据检测能力来限制人流量。

我有一些大胆的设想,比如是不是可以在大的口岸城市设立隔离特区,允许这个区域承受一定的人流。从国外入境人员需要处理事情,商务洽谈,都可以在这个特别区域进行。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2010242, encodeId=85b0201024202, content=<a href='/topic/show?id=b3599800044' target=_blank style='color:#2F92EE;'>#陆蒙吉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98000, encryptionId=b3599800044, topicName=陆蒙吉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sun Sep 06 10:31:14 CST 2020, time=2020-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043402, encodeId=f8da2043402d1, content=<a href='/topic/show?id=13304400293' target=_blank style='color:#2F92EE;'>#大规模#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44002, encryptionId=13304400293, topicName=大规模)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Sun Sep 13 18:31:14 CST 2020, time=2020-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703339, encodeId=cadc1e0333910, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Fri Mar 12 23:31:14 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305207, encodeId=abd4130520e86, content=<a href='/topic/show?id=ba392659e58' target=_blank style='color:#2F92EE;'>#体检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26597, encryptionId=ba392659e58, topicName=体检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Tue Apr 07 07:31:14 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394367, encodeId=7c88139436e38, content=<a href='/topic/show?id=6fa7508342c' target=_blank style='color:#2F92EE;'>#德国#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50834, encryptionId=6fa7508342c, topicName=德国)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Tue Apr 07 07:31:14 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535785, encodeId=4d4f1535e85dc, content=<a href='/topic/show?id=0e8a551866c' target=_blank style='color:#2F92EE;'>#抗体检测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55186, encryptionId=0e8a551866c, topicName=抗体检测)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=682812619358, createdName=tongyongming, createdTime=Tue Apr 07 07:31:14 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603363, encodeId=f9cb160336347, content=<a href='/topic/show?id=4800e091642' target=_blank style='color:#2F92EE;'>#病毒学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70916, encryptionId=4800e091642, topicName=病毒学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ed319029923, createdName=周虎, createdTime=Tue Apr 07 07:31:14 CST 2020, time=2020-04-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2010242, encodeId=85b0201024202, content=<a href='/topic/show?id=b3599800044' target=_blank style='color:#2F92EE;'>#陆蒙吉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98000, encryptionId=b3599800044, topicName=陆蒙吉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sun Sep 06 10:31:14 CST 2020, time=2020-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043402, encodeId=f8da2043402d1, content=<a href='/topic/show?id=13304400293' target=_blank style='color:#2F92EE;'>#大规模#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44002, encryptionId=13304400293, topicName=大规模)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Sun Sep 13 18:31:14 CST 2020, time=2020-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703339, encodeId=cadc1e0333910, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Fri Mar 12 23:31:14 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305207, encodeId=abd4130520e86, content=<a href='/topic/show?id=ba392659e58' target=_blank style='color:#2F92EE;'>#体检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26597, encryptionId=ba392659e58, topicName=体检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Tue Apr 07 07:31:14 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394367, encodeId=7c88139436e38, content=<a href='/topic/show?id=6fa7508342c' target=_blank style='color:#2F92EE;'>#德国#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50834, encryptionId=6fa7508342c, topicName=德国)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Tue Apr 07 07:31:14 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535785, encodeId=4d4f1535e85dc, content=<a href='/topic/show?id=0e8a551866c' target=_blank style='color:#2F92EE;'>#抗体检测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55186, encryptionId=0e8a551866c, topicName=抗体检测)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=682812619358, createdName=tongyongming, createdTime=Tue Apr 07 07:31:14 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603363, encodeId=f9cb160336347, content=<a href='/topic/show?id=4800e091642' target=_blank style='color:#2F92EE;'>#病毒学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70916, encryptionId=4800e091642, topicName=病毒学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ed319029923, createdName=周虎, createdTime=Tue Apr 07 07:31:14 CST 2020, time=2020-04-07, status=1, ipAttribution=)]
    2020-09-13 ylz8403
  3. [GetPortalCommentsPageByObjectIdResponse(id=2010242, encodeId=85b0201024202, content=<a href='/topic/show?id=b3599800044' target=_blank style='color:#2F92EE;'>#陆蒙吉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98000, encryptionId=b3599800044, topicName=陆蒙吉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sun Sep 06 10:31:14 CST 2020, time=2020-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043402, encodeId=f8da2043402d1, content=<a href='/topic/show?id=13304400293' target=_blank style='color:#2F92EE;'>#大规模#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44002, encryptionId=13304400293, topicName=大规模)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Sun Sep 13 18:31:14 CST 2020, time=2020-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703339, encodeId=cadc1e0333910, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Fri Mar 12 23:31:14 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305207, encodeId=abd4130520e86, content=<a href='/topic/show?id=ba392659e58' target=_blank style='color:#2F92EE;'>#体检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26597, encryptionId=ba392659e58, topicName=体检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Tue Apr 07 07:31:14 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394367, encodeId=7c88139436e38, content=<a href='/topic/show?id=6fa7508342c' target=_blank style='color:#2F92EE;'>#德国#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50834, encryptionId=6fa7508342c, topicName=德国)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Tue Apr 07 07:31:14 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535785, encodeId=4d4f1535e85dc, content=<a href='/topic/show?id=0e8a551866c' target=_blank style='color:#2F92EE;'>#抗体检测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55186, encryptionId=0e8a551866c, topicName=抗体检测)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=682812619358, createdName=tongyongming, createdTime=Tue Apr 07 07:31:14 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603363, encodeId=f9cb160336347, content=<a href='/topic/show?id=4800e091642' target=_blank style='color:#2F92EE;'>#病毒学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70916, encryptionId=4800e091642, topicName=病毒学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ed319029923, createdName=周虎, createdTime=Tue Apr 07 07:31:14 CST 2020, time=2020-04-07, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2010242, encodeId=85b0201024202, content=<a href='/topic/show?id=b3599800044' target=_blank style='color:#2F92EE;'>#陆蒙吉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98000, encryptionId=b3599800044, topicName=陆蒙吉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sun Sep 06 10:31:14 CST 2020, time=2020-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043402, encodeId=f8da2043402d1, content=<a href='/topic/show?id=13304400293' target=_blank style='color:#2F92EE;'>#大规模#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44002, encryptionId=13304400293, topicName=大规模)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Sun Sep 13 18:31:14 CST 2020, time=2020-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703339, encodeId=cadc1e0333910, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Fri Mar 12 23:31:14 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305207, encodeId=abd4130520e86, content=<a href='/topic/show?id=ba392659e58' target=_blank style='color:#2F92EE;'>#体检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26597, encryptionId=ba392659e58, topicName=体检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Tue Apr 07 07:31:14 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394367, encodeId=7c88139436e38, content=<a href='/topic/show?id=6fa7508342c' target=_blank style='color:#2F92EE;'>#德国#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50834, encryptionId=6fa7508342c, topicName=德国)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Tue Apr 07 07:31:14 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535785, encodeId=4d4f1535e85dc, content=<a href='/topic/show?id=0e8a551866c' target=_blank style='color:#2F92EE;'>#抗体检测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55186, encryptionId=0e8a551866c, topicName=抗体检测)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=682812619358, createdName=tongyongming, createdTime=Tue Apr 07 07:31:14 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603363, encodeId=f9cb160336347, content=<a href='/topic/show?id=4800e091642' target=_blank style='color:#2F92EE;'>#病毒学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70916, encryptionId=4800e091642, topicName=病毒学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ed319029923, createdName=周虎, createdTime=Tue Apr 07 07:31:14 CST 2020, time=2020-04-07, status=1, ipAttribution=)]
    2020-04-07 marongnuan
  5. [GetPortalCommentsPageByObjectIdResponse(id=2010242, encodeId=85b0201024202, content=<a href='/topic/show?id=b3599800044' target=_blank style='color:#2F92EE;'>#陆蒙吉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98000, encryptionId=b3599800044, topicName=陆蒙吉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sun Sep 06 10:31:14 CST 2020, time=2020-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043402, encodeId=f8da2043402d1, content=<a href='/topic/show?id=13304400293' target=_blank style='color:#2F92EE;'>#大规模#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44002, encryptionId=13304400293, topicName=大规模)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Sun Sep 13 18:31:14 CST 2020, time=2020-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703339, encodeId=cadc1e0333910, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Fri Mar 12 23:31:14 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305207, encodeId=abd4130520e86, content=<a href='/topic/show?id=ba392659e58' target=_blank style='color:#2F92EE;'>#体检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26597, encryptionId=ba392659e58, topicName=体检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Tue Apr 07 07:31:14 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394367, encodeId=7c88139436e38, content=<a href='/topic/show?id=6fa7508342c' target=_blank style='color:#2F92EE;'>#德国#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50834, encryptionId=6fa7508342c, topicName=德国)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Tue Apr 07 07:31:14 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535785, encodeId=4d4f1535e85dc, content=<a href='/topic/show?id=0e8a551866c' target=_blank style='color:#2F92EE;'>#抗体检测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55186, encryptionId=0e8a551866c, topicName=抗体检测)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=682812619358, createdName=tongyongming, createdTime=Tue Apr 07 07:31:14 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603363, encodeId=f9cb160336347, content=<a href='/topic/show?id=4800e091642' target=_blank style='color:#2F92EE;'>#病毒学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70916, encryptionId=4800e091642, topicName=病毒学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ed319029923, createdName=周虎, createdTime=Tue Apr 07 07:31:14 CST 2020, time=2020-04-07, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=2010242, encodeId=85b0201024202, content=<a href='/topic/show?id=b3599800044' target=_blank style='color:#2F92EE;'>#陆蒙吉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98000, encryptionId=b3599800044, topicName=陆蒙吉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sun Sep 06 10:31:14 CST 2020, time=2020-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043402, encodeId=f8da2043402d1, content=<a href='/topic/show?id=13304400293' target=_blank style='color:#2F92EE;'>#大规模#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44002, encryptionId=13304400293, topicName=大规模)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Sun Sep 13 18:31:14 CST 2020, time=2020-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703339, encodeId=cadc1e0333910, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Fri Mar 12 23:31:14 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305207, encodeId=abd4130520e86, content=<a href='/topic/show?id=ba392659e58' target=_blank style='color:#2F92EE;'>#体检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26597, encryptionId=ba392659e58, topicName=体检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Tue Apr 07 07:31:14 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394367, encodeId=7c88139436e38, content=<a href='/topic/show?id=6fa7508342c' target=_blank style='color:#2F92EE;'>#德国#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50834, encryptionId=6fa7508342c, topicName=德国)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Tue Apr 07 07:31:14 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535785, encodeId=4d4f1535e85dc, content=<a href='/topic/show?id=0e8a551866c' target=_blank style='color:#2F92EE;'>#抗体检测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55186, encryptionId=0e8a551866c, topicName=抗体检测)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=682812619358, createdName=tongyongming, createdTime=Tue Apr 07 07:31:14 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603363, encodeId=f9cb160336347, content=<a href='/topic/show?id=4800e091642' target=_blank style='color:#2F92EE;'>#病毒学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70916, encryptionId=4800e091642, topicName=病毒学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ed319029923, createdName=周虎, createdTime=Tue Apr 07 07:31:14 CST 2020, time=2020-04-07, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=2010242, encodeId=85b0201024202, content=<a href='/topic/show?id=b3599800044' target=_blank style='color:#2F92EE;'>#陆蒙吉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98000, encryptionId=b3599800044, topicName=陆蒙吉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c22f171, createdName=kord1982, createdTime=Sun Sep 06 10:31:14 CST 2020, time=2020-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043402, encodeId=f8da2043402d1, content=<a href='/topic/show?id=13304400293' target=_blank style='color:#2F92EE;'>#大规模#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=44002, encryptionId=13304400293, topicName=大规模)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3fce464, createdName=ylz8403, createdTime=Sun Sep 13 18:31:14 CST 2020, time=2020-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1703339, encodeId=cadc1e0333910, content=<a href='/topic/show?id=dba720e31b7' target=_blank style='color:#2F92EE;'>#专访#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20731, encryptionId=dba720e31b7, topicName=专访)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=070a30497323, createdName=flyingeagle87, createdTime=Fri Mar 12 23:31:14 CST 2021, time=2021-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1305207, encodeId=abd4130520e86, content=<a href='/topic/show?id=ba392659e58' target=_blank style='color:#2F92EE;'>#体检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26597, encryptionId=ba392659e58, topicName=体检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Tue Apr 07 07:31:14 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1394367, encodeId=7c88139436e38, content=<a href='/topic/show?id=6fa7508342c' target=_blank style='color:#2F92EE;'>#德国#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50834, encryptionId=6fa7508342c, topicName=德国)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48732500158, createdName=12498c32m68暂无昵称, createdTime=Tue Apr 07 07:31:14 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1535785, encodeId=4d4f1535e85dc, content=<a href='/topic/show?id=0e8a551866c' target=_blank style='color:#2F92EE;'>#抗体检测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55186, encryptionId=0e8a551866c, topicName=抗体检测)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=682812619358, createdName=tongyongming, createdTime=Tue Apr 07 07:31:14 CST 2020, time=2020-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1603363, encodeId=f9cb160336347, content=<a href='/topic/show?id=4800e091642' target=_blank style='color:#2F92EE;'>#病毒学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70916, encryptionId=4800e091642, topicName=病毒学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2ed319029923, createdName=周虎, createdTime=Tue Apr 07 07:31:14 CST 2020, time=2020-04-07, status=1, ipAttribution=)]
    2020-04-07 周虎

相关资讯

EBioMedicine:新冠候选疫苗初见成效,即将进入临床试验阶段!

近日,匹兹堡大学医学院的一项新研究成果给我们带来了希望的曙光

武汉无症状感染者转确诊:楼栋曾有确诊病例,不排除社区感染

武汉市卫生健康委员会4月4日发布最新新冠肺炎疫情动态,4月3日0时-24时,武汉全市新增确诊病例1例。确诊病例为无症状感染者转确诊。病例生活楼栋曾有确诊病例,不排除社区感染。全文如下:

全球疫情晚报|国外确诊病例近80万,美国连两日新增超2万

全球新冠肺炎疫情的形势严峻。据澎湃新闻不完全统计,截至北京时间4月1日19时,中国以外已有202个国家和地区出现新冠肺炎疫情,累计确诊病例超过79万例,死亡病例超过3.9万例。相较昨日,国外单日新增确

Lancet:述评:医护人员是国家最宝贵的资源!

当地时间3月21日,Lancet在线刊登述评称:医护人员是每个国家最宝贵的资源,提供足够的个人防护装备只是第一步,相应的休息、心理支持,也必不可少。

疫情带来五大难题,院长直呼太难了!

目下,新冠肺炎疫情得到有效的控制,重灾区的湖北、武汉也在解封,这是特大的好事。院长们本可以松口气了,但下面这些事情却让他们无法心静,面对疫情无所畏惧的院长们被这些问题难住了。

美CDC主任:无症状感染者达25%,疫情或持续24个月

据外媒报道,日前,美国疾病控制与预防中心(CDC)主任雷德菲尔德在接受美国全国公共广播电台(NPR)采访时表示,美国国内25%的新冠肺炎感染者为无症状感染者,疫情或在24个月内持续影响人们的生活。